Journal of Hepatocellular Carcinoma最新文献

筛选
英文 中文
Radiofrequency Ablation Therapy versus Stereotactic Body Radiation Therapy for Naive Hepatocellular Carcinoma (≤5cm): A Retrospective Multi-Center Study. 射频消融治疗与立体定向体外放射治疗用于治疗≤5 厘米的无症状肝细胞癌:一项回顾性多中心研究。
IF 4.2 3区 医学
Journal of Hepatocellular Carcinoma Pub Date : 2024-11-13 eCollection Date: 2024-01-01 DOI: 10.2147/JHC.S488138
Jing Sun, Wengang Li, Weiping He, Yanping Yang, Lewei Duan, Tingshi Su, Aimin Zhang, Tao Zhang, Xiaofang Zhao, Xiaoyun Chang, Xuezhang Duan
{"title":"Radiofrequency Ablation Therapy versus Stereotactic Body Radiation Therapy for Naive Hepatocellular Carcinoma (≤5cm): A Retrospective Multi-Center Study.","authors":"Jing Sun, Wengang Li, Weiping He, Yanping Yang, Lewei Duan, Tingshi Su, Aimin Zhang, Tao Zhang, Xiaofang Zhao, Xiaoyun Chang, Xuezhang Duan","doi":"10.2147/JHC.S488138","DOIUrl":"10.2147/JHC.S488138","url":null,"abstract":"<p><strong>Purpose: </strong>Radiofrequency ablation (RFA) is a micro-invasive treatment for early-stage HCC patients. Stereotactic body radiation therapy (SBRT) has also been proven an effective and safe treatment for HCC patients. This multi-center study is to compare the efficacy of computed tomography (CT)-guided RFA and CT-based SBRT in naïve HCC patients with tumor diameters ≤5 cm.</p><p><strong>Patients and methods: </strong>This retrospective cohort study included 1001 treatment-naïve HCC patients from three hospitals or medical centers. The patients received RFA (n = 481) or SBRT (n = 520) treatment between December 2011 and May 2019. Furthermore, subgroup analyses of all patients were conducted based on Couinaud's classification of liver segments.</p><p><strong>Results: </strong>After matching, the local control (LC) rates of the SBRT group were better than those of the RFA group (<i>p</i>=0.024*), which mainly referred to the patients whose tumors were located in the S7/S8 (<i>p</i>=0.006*). Among patients with tumors located in S1, nineteen patients (19/21) underwent SBRT. The 1-, 3- and 5-year LC rates were 100%, 87.8% and 87.8% in the SBRT group, and the 1-, 3- and 5-year OS rates were 100%, 69.8% and 69.8%, respectively. Moreover, the OS rates in S5/S6 group in RFA were higher than those in SBRT group.</p><p><strong>Conclusion: </strong>The LC rates were better in the SBRT group than in the RFA group for the patients with lesions localized in S7/S8, and SBRT could also be a therapeutic option for patients with lesions in S1. Moreover, patients with tumors located in S5/S6 were better candidates for RFA treatment than SBRT.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"11 ","pages":"2199-2210"},"PeriodicalIF":4.2,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2,2'- Bipyridine Derivatives Exert Anticancer Effects by Inducing Apoptosis in Hepatocellular Carcinoma (HepG2) Cells. 2,2'-联吡啶衍生物通过诱导肝细胞癌(HepG2)细胞凋亡发挥抗癌作用
IF 4.2 3区 医学
Journal of Hepatocellular Carcinoma Pub Date : 2024-11-09 eCollection Date: 2024-01-01 DOI: 10.2147/JHC.S479463
Priyanka, Somdutt Mujwar, Ram Bharti, Thakur Gurjeet Singh, Neeraj Khatri
{"title":"2,2'- Bipyridine Derivatives Exert Anticancer Effects by Inducing Apoptosis in Hepatocellular Carcinoma (HepG2) Cells.","authors":"Priyanka, Somdutt Mujwar, Ram Bharti, Thakur Gurjeet Singh, Neeraj Khatri","doi":"10.2147/JHC.S479463","DOIUrl":"10.2147/JHC.S479463","url":null,"abstract":"<p><strong>Purpose: </strong>To elucidate the therapeutic potential of 2,2'-bipyridine derivatives [NPS (1-6)] on hepatocellular carcinoma HepG2 cells.</p><p><strong>Methods: </strong>The effects on cell survival, colony formation, cellular and nuclear morphology, generation of reactive oxygen species (ROS), change in the integrity of mitochondrial membrane potential (MMP), and apoptosis were investigated. Additionally, docking studies were conducted to analyze and elucidate the interactions between the derivatives and AKT and BRAF proteins.</p><p><strong>Results: </strong>NPS derivatives (1, 2, 5 and 6) significantly impaired cell viability of HepG2 cell lines at nanogram range concentrations - 72.11 ng/mL, 154.42 ng/mL, 71.78 ng/mL, and 71.43 ng/mL, while other derivatives were also effective at concentrations below 1 µg/mL. These compounds reduced the colony formation capacity of HepG2 cells in a dose-dependent manner following treatment. Mechanistic studies revealed that these derivatives induce reactive oxygen species (ROS) accumulation and cause mitochondrial membrane depolarization, ultimately triggering apoptosis in HepG2 cells. In the presence of these derivatives, cells demonstrated that 75% of cells underwent apoptosis, compared to 25% in the control group. Additionally, there was a marked increase in mitochondrial depolarization (95% cells) and a threefold rise in ROS levels compared to the controls. Docking studies revealed interactions between the derivatives and the signaling proteins AKT (PDB ID: 6HHF) and BRAF (PDB ID: 8C7Y) with binding affinities ranging from -7.10 to -9.91, highlighting their pivotal role in targeting key players in hepatocellular carcinoma progression.</p><p><strong>Conclusion: </strong>The findings of this study underscore the therapeutic potential of these derivatives against HepG2 cells and offer valuable insights for further experimental validation of their efficacy as inhibitors targeting AKT or BRAF signaling pathways.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"11 ","pages":"2181-2198"},"PeriodicalIF":4.2,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11559256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Prediction and Risk Stratification of Transarterial Chemoembolization Combined with Targeted Therapy and Immunotherapy for Unresectable Hepatocellular Carcinoma: A Dual-Center Study. 经动脉化疗栓塞术联合靶向疗法和免疫疗法治疗不可切除肝细胞癌的预后预测和风险分层:一项双中心研究。
IF 4.2 3区 医学
Journal of Hepatocellular Carcinoma Pub Date : 2024-11-07 eCollection Date: 2024-01-01 DOI: 10.2147/JHC.S487080
Wendi Kang, Huafei Zhao, Qicai Lian, Hang Li, Xuan Zhou, Hao Li, Siyuan Weng, Zhentao Yan, Zhengqiang Yang
{"title":"Prognostic Prediction and Risk Stratification of Transarterial Chemoembolization Combined with Targeted Therapy and Immunotherapy for Unresectable Hepatocellular Carcinoma: A Dual-Center Study.","authors":"Wendi Kang, Huafei Zhao, Qicai Lian, Hang Li, Xuan Zhou, Hao Li, Siyuan Weng, Zhentao Yan, Zhengqiang Yang","doi":"10.2147/JHC.S487080","DOIUrl":"https://doi.org/10.2147/JHC.S487080","url":null,"abstract":"<p><strong>Purpose: </strong>The combination of transarterial chemoembolization, molecular targeted therapy, and immunotherapy (triple therapy) has shown promising outcomes in the treatment of unresectable hepatocellular carcinoma (HCC). This study aimed to build a prognostic model to identify patients who could benefit from triple therapy.</p><p><strong>Patients and methods: </strong>This retrospective study encompassed 242 patients with HCC who underwent triple therapy from two centers (Training cohort: 158 patients from the Center 1; External validation cohort: 84 patients from the Center 2). Independent predictors of overall survival (OS) and progression-free survival (PFS) were identified through Cox regression analyses, and prognostic models based on Cox proportional hazards models were developed. Prognosis was assessed using Kaplan - Meier curves.</p><p><strong>Results: </strong>In the training cohort, independent predictors of PFS included vascular invasion and the C-reactive protein and alpha-fetoprotein in immunotherapy (CRAFITY) score. Independent predictors of OS were the CRAFITY score, extrahepatic metastasis, and the neutrophil-to-lymphocyte ratio. Prognostic prediction models were constructed based on these variables. The prognostic model for OS demonstrated a C-index of 0.715 (95% confidence interval (CI), 0.662-0.768) in the training cohort and 0.701 (95% CI, 0.628-0.774) in the validation cohort. Patients were divided into low- and high-risk categories using the predictive model (P<0.001). These findings were corroborated by the external validation cohort.</p><p><strong>Conclusion: </strong>The developed prognostic model serves as a reliable and convenient tool to predict outcomes in patients with unresectable HCC undergoing triple therapy. It aids clinicians in making informed treatment decisions.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"11 ","pages":"2169-2179"},"PeriodicalIF":4.2,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancing Hepatocellular Carcinoma Management Through Peritumoral Radiomics: Enhancing Diagnosis, Treatment, and Prognosis. 通过瘤周放射组学推进肝细胞癌管理:加强诊断、治疗和预后。
IF 4.2 3区 医学
Journal of Hepatocellular Carcinoma Pub Date : 2024-11-04 eCollection Date: 2024-01-01 DOI: 10.2147/JHC.S493227
Yanhua Huang, Hongwei Qian
{"title":"Advancing Hepatocellular Carcinoma Management Through Peritumoral Radiomics: Enhancing Diagnosis, Treatment, and Prognosis.","authors":"Yanhua Huang, Hongwei Qian","doi":"10.2147/JHC.S493227","DOIUrl":"https://doi.org/10.2147/JHC.S493227","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is associated with high mortality rates due to late detection and aggressive progression. Peritumoral radiomics, an emerging technique that quantitatively analyzes the tissue surrounding the tumor, has shown significant potential in enhancing the management of HCC. This paper examines the role of peritumoral radiomics in improving diagnostic accuracy, guiding personalized treatment strategies, and refining prognostic assessments. By offering unique insights into the tumor microenvironment, peritumoral radiomics enables more precise patient stratification and informs clinical decision-making. However, the integration of peritumoral radiomics into routine clinical practice faces several challenges. Addressing these challenges through continued research and innovation is crucial for the successful implementation of peritumoral radiomics in HCC management, ultimately leading to improved patient outcomes.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"11 ","pages":"2159-2168"},"PeriodicalIF":4.2,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11546143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predicting Pathological Response of Neoadjuvant Conversion Therapy for Hepatocellular Carcinoma Patients Using CT-Based Radiomics Model. 利用基于CT的放射组学模型预测肝细胞癌患者对新辅助转换疗法的病理反应
IF 4.2 3区 医学
Journal of Hepatocellular Carcinoma Pub Date : 2024-11-01 eCollection Date: 2024-01-01 DOI: 10.2147/JHC.S487370
Haoxiang Wen, Ruiming Liang, Xiaofei Liu, Yang Yu, Shuirong Lin, Zimin Song, Yihao Huang, Xi Yu, Shuling Chen, Lili Chen, Baifeng Qian, Jingxian Shen, Han Xiao, Shunli Shen
{"title":"Predicting Pathological Response of Neoadjuvant Conversion Therapy for Hepatocellular Carcinoma Patients Using CT-Based Radiomics Model.","authors":"Haoxiang Wen, Ruiming Liang, Xiaofei Liu, Yang Yu, Shuirong Lin, Zimin Song, Yihao Huang, Xi Yu, Shuling Chen, Lili Chen, Baifeng Qian, Jingxian Shen, Han Xiao, Shunli Shen","doi":"10.2147/JHC.S487370","DOIUrl":"10.2147/JHC.S487370","url":null,"abstract":"<p><strong>Purpose: </strong>Predicting the pathological response after neoadjuvant conversion therapy for initially unresectable hepatocellular carcinoma (HCC) is essential for surgical decision-making and survival outcomes but remains a challenge. We aimed to develop a radiomics model to predict pathological responses.</p><p><strong>Methods: </strong>We included 203 patients with HCC who underwent hepatectomy after neoadjuvant conversion therapy between 2015 and 2023 and separated them into a training set (100 patients from Center A) and a validation set (103 patients from Center B). Pathological complete response (pCR)-related radiomic features were extracted from the largest tumor layer in the arterial and portal vein phases of the CT. A synthetic minority oversampling technique (SMOTE) was used to balance the minority groups in the training set. The SMOTE radiomics model was constructed using a logistic regression model in the SMOTE training set and its performance was verified in the validation set.</p><p><strong>Results: </strong>The AUC of the preoperative modified response evaluation criteria in solid tumors (mRECIST) assessment for pCR was 0.656 and 0.589 in the training and validation sets, respectively. The SMOTE radiomics model was established based on ten radiomic features and showed good pCR-predictive performance in the SMOTE training set (AUC, 0.889; accuracy, 87.7%) and the validation set (AUC: 0.843, accuracy: 86.4%). The RFS of the radiomics-predicted-pCR group was significantly better than that of the predicted-non-pCR group in the training cohort (<i>P =</i> 0.001, 2-year RFS: 69.5% and 30.1% respectively) and the validation cohort (<i>P =</i> 0.012, 2-year RFS: 65.9% and 38.0% respectively).</p><p><strong>Conclusion: </strong>The SMOTE radiomics model has great potential for predicting pathological response and evaluating RFS in patients with unresectable HCC after neoadjuvant conversion therapy.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"11 ","pages":"2145-2157"},"PeriodicalIF":4.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Outcomes of Patients with Liver Cirrhosis After Eradication of Chronic Hepatitis C with Direct-Acting Antiviral Drugs (DAAs). 使用直接作用抗病毒药物 (DAAs) 根治慢性丙型肝炎后肝硬化患者的长期疗效。
IF 4.2 3区 医学
Journal of Hepatocellular Carcinoma Pub Date : 2024-10-30 eCollection Date: 2024-01-01 DOI: 10.2147/JHC.S475810
Mohsen Salama, Nehad Darwesh, Maha Mohammad Elsabaawy, Eman Abdelsameea, Asmaa Gomaa, Aliaa Sabry
{"title":"Long-Term Outcomes of Patients with Liver Cirrhosis After Eradication of Chronic Hepatitis C with Direct-Acting Antiviral Drugs (DAAs).","authors":"Mohsen Salama, Nehad Darwesh, Maha Mohammad Elsabaawy, Eman Abdelsameea, Asmaa Gomaa, Aliaa Sabry","doi":"10.2147/JHC.S475810","DOIUrl":"10.2147/JHC.S475810","url":null,"abstract":"<p><strong>Purpose: </strong>This research was designed to determine the long-term outcomes in patients with liver cirrhosis who achieved sustained virological response (SVR) after direct-acting anti-viral drugs (DAAs) based regimens.</p><p><strong>Patients and methods: </strong>This study involved 193 patients with HCV-related cirrhosis who had previously completed DAAs regimens and accomplished SVR. Clinical, laboratory, and radiological features at the first and 3rd-year follow-up after the end of treatment were analyzed. Overall survival (OS) and incidence of liver decompensation or hepatocellular carcinoma (HCC) were determined at the 5-year follow-up.</p><p><strong>Results: </strong>About 68.4% of our patients with HCV-related cirrhosis were males and their mean age was 54.8 ± 7.7 years. Follow-up at the first and the 3rd-year showed significant improvements in albumin (<i>P</i> = 0.001), liver enzymes (<i>P</i> = 0.001), alpha-fetoprotein (AFP) (<i>P</i> < 0.001), platelet count (<i>P</i> = 0.001), the model for end-stage liver disease (MELD) score (<i>P</i> = 0.001 and 0.01), FIB4 and Aspartate Aminotransferase-to-Platelet Ratio Index (APRI) scores (<i>p</i> < 0.001). The liver stiffness (LS) also significantly improved (<i>p</i> = 0.001). At the 5th year, the mean OS was 58.3 months, with 14.5% and 17.6% of patients developing de-novo HCC and decompensation, respectively. The mean OS at the 5th-year follow-up was shorter in patients who developed HCC and those with liver decompensation (<i>p</i> = 0.001). Alfa-fetoprotein and LS are predictive factors for HCC development.</p><p><strong>Conclusion: </strong>Despite achieving SVR, continuous surveillance for HCC and new-onset decompensation is mandatory in patients with liver cirrhosis.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"11 ","pages":"2115-2132"},"PeriodicalIF":4.2,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Circulating Biomarkers Predict Immunotherapeutic Response in Hepatocellular Carcinoma Using a Machine Learning Method. 循环生物标记物利用机器学习方法预测肝细胞癌的免疫治疗反应
IF 4.2 3区 医学
Journal of Hepatocellular Carcinoma Pub Date : 2024-10-30 eCollection Date: 2024-01-01 DOI: 10.2147/JHC.S474593
Zhiyan Dai, Chao Chen, Ziyan Zhou, Mingzhen Zhou, Zhengyao Xie, Ziyao Liu, Siyuan Liu, Yiqiang Chen, Jingjing Li, Baorui Liu, Jie Shen
{"title":"Circulating Biomarkers Predict Immunotherapeutic Response in Hepatocellular Carcinoma Using a Machine Learning Method.","authors":"Zhiyan Dai, Chao Chen, Ziyan Zhou, Mingzhen Zhou, Zhengyao Xie, Ziyao Liu, Siyuan Liu, Yiqiang Chen, Jingjing Li, Baorui Liu, Jie Shen","doi":"10.2147/JHC.S474593","DOIUrl":"10.2147/JHC.S474593","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitor (ICI) therapy is a promising treatment for cancer. However, the response rate to ICI therapy in hepatocellular carcinoma (HCC) patients is low (approximately 30%). Thus, an approach to predict whether a patient will benefit from ICI therapy is required. This study aimed to design a classifier based on circulating indicators to identify patients suitable for ICI therapy.</p><p><strong>Methods: </strong>This retrospective study included HCC patients who received immune checkpoint inhibitor therapy between March 2017 and September 2023 at Nanjing Drum Tower Hospital and Jinling Hospital. The levels of the 17 serum biomarkers and baseline patients' characters were assessed to discern meaningful circulating indicators related with survival benefits using random forest. A prognostic model was then constructed to predict survival of patients after treatment.</p><p><strong>Results: </strong>A total of 369 patients (mean age 56, median follow-up duration 373 days,) were enrolled in this study. Among the 17 circulating biomarkers, 11 were carefully selected to construct a classifier. Receiver operating characteristic (ROC) analysis yielded an area under the curve (AUC) of 0.724. Notably, patients classified into the low-risk group exhibited a more positive prognosis (<i>P</i> = 0.0079; HR, 0.43; 95% CI 0.21-0.87). To enhance efficacy, we incorporated 11 clinical features. The extended model incorporated 12 circulating indicators and 5 clinical features. The AUC of the refined classifier improved to 0.752. Patients in the low-risk group demonstrated superior overall survival compared with those in the high-risk group (<i>P</i> = 0.026; HR 0.39; 95% CI 0.11-1.37).</p><p><strong>Conclusion: </strong>Circulating biomarkers are useful in predicting therapeutic outcomes and can help in making clinical decisions regarding the use of ICI therapy.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"11 ","pages":"2133-2144"},"PeriodicalIF":4.2,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Comparative Study of Surgical Approaches for Hepatocellular Carcinoma: Conversion versus Direct Resection. 肝细胞癌手术方法的比较研究:转换与直接切除。
IF 4.2 3区 医学
Journal of Hepatocellular Carcinoma Pub Date : 2024-10-29 eCollection Date: 2024-01-01 DOI: 10.2147/JHC.S483397
Xinlin Li, Kai Chen, Xu Feng, Xinhua Wu, Shiguai Qi, Qingmiao Wang, Zhengrong Shi
{"title":"A Comparative Study of Surgical Approaches for Hepatocellular Carcinoma: Conversion versus Direct Resection.","authors":"Xinlin Li, Kai Chen, Xu Feng, Xinhua Wu, Shiguai Qi, Qingmiao Wang, Zhengrong Shi","doi":"10.2147/JHC.S483397","DOIUrl":"10.2147/JHC.S483397","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of This study is exploring the intraoperative and perioperative differences between patients undergoing conversion surgery and those undergoing direct surgery, so as to improve preoperative preparation.</p><p><strong>Methods: </strong>The retrospective study was approved by an ethics review committee. A total of 232 patients with hepatocellular carcinoma who underwent surgical resection at the First Affiliated Hospital of Chongqing Medical University from September 2022 to December 2023 were included, comprising 210 operating patients and 53 conversion patients. Propensity score matching was employed for comparison in order to minimize bias.</p><p><strong>Results: </strong>The conversion group had more intraoperative bleeding (each P=0.001), longer operation time (P=0.033; PSM p=0.025), and higher intraoperative blood transfusion rate (p=0.001; PSM p=0.044). The incidence of perioperative complications, including perioperative ascites formation (p=0.011; PSM p=0.005), moderate to severe anemia (p=0.001; PSM p=0.002), postoperative blood transfusion (p=0.004; PSM p=0.036), and postoperative ICU transfer (p=0.041; PSM p=0.025), was higher in the conversion group compared to the operation group. The postoperative hospital stay (p=0.001; PSM p=0.003) was prolonged in the conversion group.</p><p><strong>Conclusion: </strong>Post-conversion operations carry a higher risk of bleeding and are more likely to result in moderate to severe anemia and ascites formation in the perioperative period. However, the risk is reversible with adequate preoperative blood preparation and prompt postoperative symptomatic treatment. Conversion patients should be encouraged to undergo operating therapy when they can withstand surgical resection.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"11 ","pages":"2101-2113"},"PeriodicalIF":4.2,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FOLFOX-Based Hepatic Arterial Infusion Chemotherapy with Sequential Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Large Hepatocellular Carcinoma: A Single-Center Retrospective Cohort Study. 基于 FOLFOX 的肝动脉灌注化疗联合序贯药物洗脱珠经动脉化疗栓塞治疗不可切除的大肝细胞癌:一项单中心回顾性队列研究。
IF 4.2 3区 医学
Journal of Hepatocellular Carcinoma Pub Date : 2024-10-28 eCollection Date: 2024-01-01 DOI: 10.2147/JHC.S493577
Rongce Zhao, Jing Zhou, Zehao Zheng, Xinhao Xiong, Qiaoxuan Wang, Shaohua Li, Wei Wei, Rongping Guo
{"title":"FOLFOX-Based Hepatic Arterial Infusion Chemotherapy with Sequential Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Large Hepatocellular Carcinoma: A Single-Center Retrospective Cohort Study.","authors":"Rongce Zhao, Jing Zhou, Zehao Zheng, Xinhao Xiong, Qiaoxuan Wang, Shaohua Li, Wei Wei, Rongping Guo","doi":"10.2147/JHC.S493577","DOIUrl":"10.2147/JHC.S493577","url":null,"abstract":"<p><strong>Background: </strong>For patients with large unresectable hepatocellular carcinoma (HCC), the effectiveness of conventional transarterial chemoembolization (TACE) remains suboptimal, which necessitates the administration of substantial volumes of chemotherapy drugs and lipiodol, thereby increasing the risk of liver failure and other chemotherapy-related complications. Therefore, we devised a strategy of initial hepatic arterial infusion chemotherapy (HAIC) followed by sequential drug-eluting bead TACE (DEB-TACE). In our treatment design, a lower tumor burden after HAIC facilitated complete embolization of tumor vasculature, and the use of less amount of embolic agents reduced the incidence of liver failure and embolization syndromes.</p><p><strong>Methods: </strong>This retrospective study evaluated consecutive patients with unresectable large HCC with a maximum tumor diameter of ≥7 cm who received FOLFOX-HAIC combined with sequential DEB-TACE from April 2019 to February 2024. Efficacy was evaluated using the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS); and safety was assessed using the frequency of key adverse events (AEs).</p><p><strong>Results: </strong>Among the 76 patients included, the median maximum tumor diameter was 12.4 cm (range, 7.0-23.4 cm). The overall ORRs based on mRECIST and RECIST 1.1 criteria were 94.1% and 51.5%, respectively. The median OS was 28.1 months (95% CI, 22.7-33.4), and the median PFS was 11.7 months (95% CI, 7.7-15.8). All patients experienced AEs, but only 18.4% experienced grade 3 or 4 AEs, there was no treatment-related mortality.</p><p><strong>Conclusion: </strong>In this single-center, retrospective study, our results suggested that FOLFOX-HAIC with sequential DEB-TACE demonstrated promising efficacy and safety for patients with unresectable HCC with a maximum tumor diameter of ≥7 cm.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"11 ","pages":"2087-2099"},"PeriodicalIF":4.2,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11529345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gamma-Glutamyl Transpeptidase to Neutrophil Ratio as Prognostic Indicator for Hepatocellular Carcinoma Patients Post-Curative Resection. γ-谷氨酰转肽酶与中性粒细胞比率作为肝细胞癌患者根治性切除术后的预后指标
IF 4.2 3区 医学
Journal of Hepatocellular Carcinoma Pub Date : 2024-10-27 eCollection Date: 2024-01-01 DOI: 10.2147/JHC.S478186
Xueqin Shen, Xiaoping Niu
{"title":"Gamma-Glutamyl Transpeptidase to Neutrophil Ratio as Prognostic Indicator for Hepatocellular Carcinoma Patients Post-Curative Resection.","authors":"Xueqin Shen, Xiaoping Niu","doi":"10.2147/JHC.S478186","DOIUrl":"10.2147/JHC.S478186","url":null,"abstract":"<p><strong>Background: </strong>The close association between inflammation and the clinical outcomes of hepatocellular carcinoma (HCC) has been extensively documented. This study aims to analyze the association between a novel inflammatory indicator, the gamma-glutamyl transpeptidase to neutrophil ratio (GNR), and HCC prognosis following curative resection.</p><p><strong>Methods: </strong>A cohort of 204 eligible HCC cases were included. Based on an optimal cut-off value determined utilizing the X-tile software, patients were categorized into low- and high-GNR groups. The overall survival (OS) and recurrence-free survival (RFS) rates were assessed using the Kaplan-Meier analysis method with Log rank tests. Multivariate Cox proportional hazard regression was used to investigate the independent association between GNR and HCC prognosis. Restricted cubic splines were used to explore the nonlinear relationship between GNR and the risk of death or recurrence.</p><p><strong>Results: </strong>The low GNR group exhibited significantly higher 3-year OS and RFS rates than the high GNR group. Multivariate Cox analysis indicated that a high GNR level was independently associated with poor OS and RFS. A linear correlation between GNR and the risk of death, as well as a nonlinear inverted \"U\" shape correlation between GNR and the risk of recurrence, were observed.</p><p><strong>Conclusion: </strong>The findings provide evidence supporting the independent association of GNR with HCC prognosis. These results offer promise for enhancing prognosis assessments and guiding active monitoring strategies for patients with HCC post-curative resection.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"11 ","pages":"2077-2085"},"PeriodicalIF":4.2,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信